Search alternatives:
point decrease » point increase (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a de » _ de (Expand Search), a d (Expand Search), i de (Expand Search)
point decrease » point increase (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a de » _ de (Expand Search), a d (Expand Search), i de (Expand Search)
-
821
-
822
A decrease in the invasiveness of <i>Candida albicans</i> into Caco-2 cells parallels the differentiation of intestinal epithelial cells.
Published 2016“…The gene expression levels of Apolipoprotein A-IV (ΔΔCt) were statistically lower after 1, 2, 3 and 5 days post-seeding than at day 15 as a result of incomplete differentiation (*<i>p <</i> 0.05, Mann–Whitney test). …”
-
823
-
824
-
825
-
826
-
827
-
828
-
829
-
830
-
831
Significant decrease of SMAD4 protein in DBA iPSCs.
Published 2015“…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”
-
832
-
833
Decreased biomechanical stability of bones from <i>Col1a1-Krm2</i> transgenic mice.
Published 2013“…(D) Cortical thickness (C.Th.) and bone mineral density (vBMD) are decreased in <i>Col1a1-Krm2</i> transgenic mice compared to wildtype littermates. …”
-
834
-
835
A R13A point mutation in C4 attenuates CLCuMuV infection.
Published 2018“…<b>(C)</b> The mutant CLCuMuV carrying C4<sup>R13A</sup> (CLCuMuV-C4<sup>R13A</sup>), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”
-
836
-
837
-
838
-
839
-
840
S5 Fig -
Published 2024“…Cost-based pricing models are discussed as a possibility for cost containment. This study focuses on two drugs, pembrolizumab (Keytruda) and daratumumab (Darzalex), to explore the potential effect of indication broadening on the estimated price when using the cost-based pricing (CBP) model proposed by Uyl-de Groot and Löwenberg (2018).…”